DOCETAXEL
Manufacturer: Armas Pharmaceuticals Inc.
Score: 141.0
Docetaxel is an antineoplastic agent used for the treatment of various cancers, including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. It works by disrupting the microtubular network in cells, leading to inhibition of mitosis and cell death. The recommended dose and schedule of docetaxel varies depending on the specific cancer type and patient population. Important safety information includes warnings about toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention. Contraindications include hypersensitivity to docetaxel or polysorbate 80, and neutrophil counts below 1500 cells/mm^3. Special population considerations include use in pregnancy, nursing mothers, pediatric patients, and geriatric patients.
Toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention have been reported with docetaxel use.
Dose adjustments may be necessary based on neutrophil counts, platelet counts, and liver function.
60-100 mg/m^2 every 3 weeks
Not established
75 mg/m^2 every 3 weeks
Not established
75 mg/m^2 every 3 weeks
Not established
75 mg/m^2 every 3 weeks
Not established
75 mg/m^2 every 3 weeks
Not established